ChemoMetec 将来の成長

Future 基準チェック /36

ChemoMetec利益と収益がそれぞれ年間17.2%と14.3%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に26.8% 17.1%なると予測されています。

主要情報

17.2%

収益成長率

17.1%

EPS成長率

Life Sciences 収益成長	26.4%
収益成長率	14.3%
将来の株主資本利益率	26.8%
アナリストカバレッジ	Low
最終更新日	11 Nov 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

DB:CHY - アナリストの将来予測と過去の財務データ ( )DKK Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
6/30/2027	629	234	185	249	3
6/30/2026	547	202	164	219	3
6/30/2025	475	175	158	205	3
6/30/2024	408	136	85	129	N/A
3/31/2024	405	140	98	138	N/A
12/31/2023	402	144	111	147	N/A
9/30/2023	423	161	112	150	N/A
6/30/2023	444	179	113	154	N/A
3/31/2023	453	179	117	156	N/A
12/31/2022	461	180	120	158	N/A
9/30/2022	445	170	120	167	N/A
6/30/2022	428	159	121	177	N/A
3/31/2022	393	145	94	148	N/A
12/31/2021	358	131	67	119	N/A
9/30/2021	320	110	75	114	N/A
6/30/2021	281	88	83	108	N/A
3/31/2021	262	81	79	105	N/A
12/31/2020	243	74	75	103	N/A
9/30/2020	229	67	60	87	N/A
6/30/2020	214	59	45	72	N/A
3/31/2020	206	54	39	66	N/A
12/31/2019	197	48	32	61	N/A
9/30/2019	186	45	32	60	N/A
6/30/2019	176	42	31	58	N/A
3/31/2019	158	37	26	50	N/A
12/31/2018	141	33	21	42	N/A
9/30/2018	127	25	15	34	N/A
6/30/2018	113	18	9	25	N/A
3/31/2018	107	15	N/A	20	N/A
12/31/2017	102	13	N/A	14	N/A
9/30/2017	96	10	N/A	12	N/A
6/30/2017	90	7	N/A	10	N/A
3/31/2017	88	6	N/A	13	N/A
12/31/2016	85	5	N/A	16	N/A
9/30/2016	85	8	N/A	17	N/A
6/30/2016	85	10	N/A	17	N/A
3/31/2016	80	11	N/A	16	N/A
12/31/2015	75	12	N/A	14	N/A
9/30/2015	68	10	N/A	14	N/A
6/30/2015	61	8	N/A	13	N/A
3/31/2015	56	5	N/A	9	N/A
12/31/2014	51	3	N/A	5	N/A
9/30/2014	48	2	N/A	5	N/A
6/30/2014	45	1	N/A	6	N/A
3/31/2014	44	1	N/A	6	N/A
12/31/2013	43	1	N/A	6	N/A

アナリストによる今後の成長予測

収入対貯蓄率: CHYの予測収益成長率 (年間17.2% ) は貯蓄率 ( 1% ) を上回っています。

収益対市場: CHYの収益 ( 17.2% ) German市場 ( 20.8% ) よりも低い成長が予測されています。

高成長収益: CHYの収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: CHYの収益 ( 14.3% ) German市場 ( 5.6% ) よりも速いペースで成長すると予測されています。

高い収益成長: CHYの収益 ( 14.3% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: CHYの自己資本利益率は、3年後には高くなると予測されています ( 26.8 %)

ChemoMetec 将来の成長

Future 基準チェック /36

主要情報

今後の成長に関する最新情報

ChemoMetec A/S Maintains Earnings Guidance for the Full-Year 2024-2025

ChemoMetec A/S Revises Earnings Guidance for the Financial Year 2024/2025

ChemoMetec A/S provides earnings guidance for the year 2024/25

ChemoMetec A/S Provides Earnings Guidance for the Year 2023/24

ChemoMetec A/S Maintains Earnings Guidance for the Year 2024

ChemoMetec A/S Affirms Earnings Guidance for the Fiscal Year 2022/2023

Recent updates

Deputy Chairman & Senior Advisor recently bought €428k worth of stock

Investor sentiment improves as stock rises 27%

Now 52% overvalued after recent price rise

ChemoMetec A/S Maintains Earnings Guidance for the Full-Year 2024-2025

Insufficient new directors

ChemoMetec A/S (CPSE:CHEMM) completed the acquisition of Ovizio Imaging Systems NV/SA.

Investor sentiment improves as stock rises 23%

ChemoMetec A/S Revises Earnings Guidance for the Financial Year 2024/2025

ChemoMetec A/S Approves Dividend

Upcoming dividend of kr.4.00 per share

ChemoMetec A/S (CPSE:CHEMM) submitted an indicative offer to acquire Ovizio Imaging Systems NV/SA.

Dividend of kr.4.00 announced

Full year 2024 earnings released: EPS: kr.7.83 (vs kr.10.27 in FY 2023)

ChemoMetec A/S provides earnings guidance for the year 2024/25

ChemoMetec A/S to Report Fiscal Year 2025 Results on Sep 11, 2025

Investor sentiment improves as stock rises 20%

ChemoMetec A/S Announces CFO Changes

Investor sentiment improves as stock rises 15%

Now 24% overvalued

Investor sentiment deteriorates as stock falls 19%

ChemoMetec A/S Provides Earnings Guidance for the Year 2023/24

Investor sentiment deteriorates as stock falls 17%

ChemoMetec A/S Announces CEO Changes

Investor sentiment improves as stock rises 32%

First half 2024 earnings released: EPS: kr.4.05 (vs kr.6.06 in 1H 2023)

ChemoMetec A/S Maintains Earnings Guidance for the Year 2024

ChemoMetec A/S Announces Executive Changes

Investor sentiment improves as stock rises 22%

Investor sentiment improves as stock rises 27%

Now 20% undervalued after recent price drop

Investor sentiment improves as stock rises 15%

Upcoming dividend of kr.6.00 per share at 1.8% yield

Chemometec A/S Proposes Dividend for the 2022/23 Financial Year

Full year 2023 earnings released: EPS: kr.10.27 (vs kr.9.16 in FY 2022)

New minor risk - Financial data availability

ChemoMetec A/S to Report Fiscal Year 2024 Results on Sep 11, 2024

ChemoMetec A/S Affirms Earnings Guidance for the Fiscal Year 2022/2023

Investor sentiment improves as stock rises 16%

Investor sentiment deteriorates as stock falls 25%

First half 2023 earnings released: EPS: kr.6.06 (vs kr.4.90 in 1H 2022)

ChemoMetec A/S Updates Earnings Guidance for the Fiscal Year 2022/2023

Investor sentiment deteriorated over the past week

Chemometec A/S Announces Resignation of Steen Søndergaard as CEO

Less than half of directors are independent

ChemoMetec A/S Provides Earnings Guidance for the Financial Year 2022-23

Investor sentiment deteriorated over the past week

Full year 2022 earnings released: EPS: kr.9.16 (vs kr.5.08 in FY 2021)

ChemoMetec A/S Provides Revenue Guidance for the Fiscal Year 2023

ChemoMetec A/S, Annual General Meeting, Oct 12, 2023

Less than half of directors are independent

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Upcoming dividend of kr.4.00 per share

Full year 2021 earnings released: EPS kr.5.08 (vs kr.3.51 in FY 2020)

New 90-day high: €80.40

First half 2021 earnings released: EPS kr.2.43 (vs kr.1.68 in 1H 2020)

New 90-day high: €76.60

New 90-day high: €66.30

New 90-day high: €60.70

Full year earnings released - EPS €3.51

New 90-day high: €54.00

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘